NuLife to Present at the LD Micro San Francisco Summit

NEWPORT BEACH, CA--(Marketwired - September 05, 2017) - NuLife Sciences (OTCQB: NULF), a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs, today announced that management will attend the LD Micro Summit in San Francisco, CA on Tuesday, September 5, 2017.

John Hollister, CEO of NuLife Sciences, is scheduled to present to as follows:

LD Micro San Francisco Summit
Date: Tuesday, September 5, 2017
Presentation Time: 9:20 a.m. Pacific Time
Location: Sir Francis Drake Hotel in San Francisco

This event is by invitation only for investors and analysts. If interested in attending, please contact Ted Haberfield with MZ Group at 760-755-2716 or thaberfield@mzgroup.us.

About NuLife Sciences

NuLife Sciences Inc. (OTCQB: NULF) a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including organ and tissue transplants, regenerative medicine, cell therapy, and wound care. NuLife Sciences Inc. operates through two wholly-owned subsidiaries, NuLife BioMed and NuLife Medical. NuLife BioMed is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. NuLife BioMed is currently in preclinical trials involving animal studies on its pathway to commercialization. NuLife Medical focuses on applying the NuLife Technique to the treatment of chronic wounds that resist closure or healing, such as diabetic foot ulcers. For more information please visit www.nulifesciences.us.

Safe Harbor

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond the Company's control. The Company's actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this press release. All statements, other than statements of historical facts, included in this press release regarding the Company's growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this press release, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this press release are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. The Company discloses important factors that could cause the Company's actual results to differ materially from its expectations under "Risk Factors" and elsewhere in this press release. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.